NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
A live webcast of the conference presentation will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events & Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies. For more information, visit www.newlinkgenetics.com, and follow us on Twitter @NLNKGenetics.
Director of Investor Relations
Public & Media Relations
617-374-8800, ext. 109
News Provided by Acquire Media